Skip to content
EN
brief us →

23andMe Holding Co.: control, breach, bankruptcy and the sale of genetic data

23andMe Holding Co.: participants and roles

Owners, the Virgin sponsor chain, group companies, officers, lenders, advisers, buyers, the plan trust and parties to proceedings connected with Chrome Holding Co. (formerly 23andMe Holding Co.), with the period and source of each role.

published
25 oct 2026
records as of
17 oct 2026
entities
208
sources
112
cite entities.csv
Holder of the Class B super-voting block (49.20% of the vote on July 1, 2024); converted its 4,931,692 Class B shares into Class A in June 2025Person with significant control (75% or more of shares and votes)Supporting investor in the SPVFounding general partnerCo-founderCo-founderFounding independent board directorSole member of ABeeC 2.0, LLCIndirect holder of the Class B block as sole member of ABeeC 2.0, LLC, sharing voting and dispositive powerGuarantor of the purchase price and lead sponsor of the buyerManager who signed the LLC's Schedule 13D filingsDirectorChief executive officer and director of VGACDirectorChief executive officer and director of the sister blank check companyChief executive officer and director of the sister blank check companyDirectorDirectorDirectorMay remove and replace the trustee's directors and so may be deemed to control itHolder of consent rights over the trustee's exercise of control of Virgin Group HoldingsSole holder of the voting shares, as trustee of trusts for members of Branson's family and related philanthropic causesObjector to the sale (amicus motion of June 18, 2025) and appellant against the sale orderHolder of 75% or more of the shares and votesDirector (as listed by an aggregator)Independent director (audit committee)Director of 23andMe, Inc.Director (as listed by an aggregator)Director (as listed by an aggregator)Managing MemberIndependent director and audit committee memberDirector (as listed by an aggregator)Owner of all the 'A' membership interests, deemed to control itOwner of Virgin Group Holdings and deemed indirect beneficial owner of the sponsor's founder shares (+1)Deemed indirect beneficial owner of the sponsor's sharesFormer holder of all the ordinary shares (transferred to the trustee on November 1, 2023); keeps the indirect ability to appoint and remove managementVice Chair and West Region and San Francisco Managing Partner; earlier Managing Partner, Silicon ValleyDirectorIndependent director of VGAC and chair of its audit committeeDirectorDirector (still a director in May 2026, according to an insider-trading report)DirectorSupporting investor in the SPVSeventeen years at the firmFounder, chairman and chief executive officerOperating partnerIndependent director of VGACChief executive officerChief executive officerState objecting to the genetic-data sale, appellant against the sale order, claimant of an administrative penalty claim and plaintiff in an enforcement suitIndependent director (audit and compensation committees)Director of 23andMe, Inc.Director (as listed by an aggregator)Founder and director (as listed by an aggregator)Managing General Partner of Xfund (aggregator: of Xfund Management Co. LLC since 2012)Managing Director of the general partner; signed the fund's Form DAdministrative claimant for unpaid cloud-service invoices ($4,061,000 reserved; settled with the trust for $6.11 million)Sole managing member and manager of VGAC's sponsorSole managing member and managerSole shareholderCo-founderChairman and chief executive officerChairmanChairman and chief executive officerSVP of marketing and public sector collaborationsSupporting investor in the SPVA lead sponsor of the SPVGeneral partner of funds sharing voting and dispositive power over 6% of the Class A shares (Farallon Capital Partners, L.P.: 5.00% on July 1, 2025)DirectorIndependent director and audit committee memberPresident and chief executive officerPrincipal of the consulting firmDirectorVice Chairman (as listed by an aggregator)Independent Class II director, audit committee chair and Special Committee memberExecutive vice president and chief financial officerDirectorChief financial officerParent of funds holding 7.79% of the voteIndependent director and audit committee chairChief financial officerChief financial officerIndependent Class I director and Special Committee memberDirectorDirector and audit committee chairChief financial officerDirect holder of 39,660,487 Class B shares (12.28% of the vote after the merger)Indirect holder, through Glaxo Group Limited, of 23.82% of the Class B shares and 19.78% of the voteAdviser to funds holding 9.44% of the voteExecutive leadership as a Bambu general partner, in an operational roleDirector (former)President and chief executive officerBoard member appointed by Governor Jerry BrownDirectorIndependent director (Special Committee)Senior vice president and general counselChief Administrative Officer (a named executive officer for fiscal 2024)General counselDirector (as listed by an insider-filings aggregator)Chief Therapeutics Officer (a named executive officer for fiscal 2024)Insured under a $5,000,000 layer of cyber and liability cover; party to the policy buyback settlementClient of the restructuring adviser, which provided the chief restructuring officerLegal address care of Corporation Service Company in Wilmington, Delaware (GLEIF record)Counterparty, with a GSK affiliate, to the exclusive drug-discovery collaboration (July 2018 – July 2023), amended into a non-exclusive data licenceLicensor of data to GSK; recognised $19.3 million on GSK's data use notice in fiscal 2025Insured under a $2,500,000 layer of cyber and liability cover; party to the policy buyback settlementSole shareholder of the operating company (renamed ChromeCo, Inc. in 2025) (+1)Registered agent in Delaware (as shown by an aggregator)Borrower and grantor of security under the debtor-in-possession financingDebtor retaining Kroll as claims and noticing agentDebtor whose plan leaves the landlord's lease claim undischarged until distributions are madeInsured under a $2,500,000 layer of cyber and liability cover; party to the policy buyback settlementGroup parent of a debtor subsidiarySole shareholder of Lemonaid Health, Inc. after its acquisition (+1)Parent of its only foreign subsidiary, disposed of on August 1, 2023Group parent of a debtor subsidiaryGroup parent of a debtor subsidiaryGroup parent of a debtor subsidiaryGroup parent of a debtor subsidiaryGroup parent of a debtor subsidiaryGroup parent of a debtor subsidiaryGroup parent of a debtor subsidiaryParent of the merger subsidiary that merged into 23andMe, Inc.Listed issuer of Class A common stock (ticker ME)Parent company of 23andMe Pharmacy Holdings, Inc. (renamed Chrome Pharmacy Holdings, Inc.)Wind-down debtor whose assets other than the Lemonaid interests vested in the trust; its shares were cancelled and its board dissolved, the Plan Administrator becoming its sole officer and directorSeller to TTAM, through the NewCo equity sale, of substantially all the Chrome debtors' assets, including customers' genetic data, for $302.5 million in cash plus assumed liabilitiesProvider of research services under a five-year agreement to build lung-cancer research cohorts ($5.4 million under the first statement of work)Registered agent in Delaware (as shown by an aggregator)Former tenant of the landlord's San Francisco building; rejected the lease after the asset saleEngaged director Richard Scheller as a consultant ($10,000 a month at the start; $120,000 paid in fiscal 2024)Partner in forming the SPV; its principals sit on the boardUnsecured creditor appointed to the official creditors' committeeManaging Partner of the Silicon Valley officeDirectorU.S. Managing Partner for audit and enterprise risk services in technology and for venture capital servicesDirectorDirectorIndependent Class II director, Lead Independent Director and compensation committee chair; chairman of the board from March 21, 2025; Special Committee memberDirector and audit committee chairChief financial officerDirectorDirectorIndependent registered public accounting firm (auditor since 2020)Managing DirectorChief restructuring officer, provided by Alvarez & Marsal; foreign representative in the Canadian recognition proceedingsInterim chief financial officerInterim chief financial officer (signed a Sarbanes-Oxley certification of the 2022 annual report)Interim chief financial officerUnsecured creditor appointed to the official creditors' committeeCreditor objecting to the debtors' treatment of its lease-rejection claim and appellant against the confirmation orderIndependent director of VGACDirectorVice ChairmanChief financial officer and director of VGAC; then Class III director of the combined companyInvestment professionalChief financial officer and director of the sister blank check companyBoard memberFounding partnerManaging PartnerPersonal holder of Class A shares reporting jointly with Zentree (858,813 shares in November 2024; 3,132,593 on March 28, 2025)DirectorFounder and chief executive officerIndependent director (compensation committee)Director of 23andMe, Inc.Independent directorIndependent directorChief executive officerClass II director and chair of the compensation committeeFounder and former director of the Center for Women's Health ResearchPresident and dean (at the school since 2011)Director (reporting person in insider filings)Holder of 5.73% of the Class A sharesRegistered agent in Delaware (as shown by an aggregator)General partnerChief operating officer; one of the Bambu general partners named to lead the buyerInitial successful bidder ($256 million) under an asset purchase agreement, then outbid by TTAM and named backup bidderRival bidder for the genetic-testing business (Regeneron first chosen, TTAM backup; then TTAM winner and Regeneron backup at $151 million)Head of Therapeutics Discovery; executive officer from August 8, 2023 to August 23, 2024Board member alongside Innova's principalsDirectorIndependent directorBoard member from 2018 and chairman of R&D from 2019 (senior advisor)DirectorExecutive vice president of research and early developmentNon-independent directorChief scientific officer and head of therapeutics (2015–2019); director from 2019DirectorIndependent director (as listed by an aggregator)Chief financial and accounting officer from August 2022; interim chief executive officer and president from March 23, 2025; chief executive officer by December 2025Vice president and chief financial officerChief financial officerDirectorChief financial officerConsultantEntity of the Sequoia Capital group whose directors exercised voting and investment discretion over 10.70% of the Class B shares (8.89% of the vote)Sponsor of VGAC holding all 12,623,750 founder shares (99.29% of Class B, 19.86% of all ordinary shares) and the sole right to elect directors before the mergerBuyer from Chrome Holding Co. under the stock purchase agreement for the Lemonaid companies ($10 million plus cure payments)Buyer of all the shares of Lemonaid Health, Inc.Buyer of all the shares of Chrome Pharmacy Holdings, Inc.SisterTreasurer and secretary (unpaid)Director and officer; President until September 2024PresidentIndependent non-executive chairmanIndependent Class III director, chair of the audit committee and member of the Special CommitteeDirectorChairmanUnsecured creditor appointed to the official creditors' committeeState objecting to the genetic-data sale, plaintiff in its own adversary proceeding (No. 25-04036) and signatory governmental claimant allotted $1,266,860 of the 2026 settlementBuyer whose released parties under the third amended plan included ABeeC 2.0, LLCBuyer whose released parties under the third amended plan included the Anne Wojcicki FoundationBuyer that the wind-down debtors said had assumed the Converge invoicesBuyer-side party in the bankruptcy case (formerly TTAM Employee Company)Buyer-side party in the bankruptcy case (formerly 23andMe PGS LLC)Intervenor-appellee with the debtors in the appeal of California and others against the sale order (+1)Buyer said by the wind-down debtors to have assumed the Converge invoices under the purchase agreement (trust keeps a reimbursement right)Stalking-horse plan sponsor for the reorganised Lemonaid equity at $2.5 millionBuyer-side party in the bankruptcy case (formerly TTAM Research Company, LLC)Buyer-side party in the bankruptcy case, represented by the same law firmRegistered person with significant control (+1)Holder of 6.64% of the Class A sharesSole shareholderOwner of Corvina Holdings Limited, the sponsor's managerIndirect owner through Corvina Holdings LimitedIndependent Class I directorIndependent Class III director and member of the Special Committee; led the independent investigation (+1)Partner (bankruptcy and restructuring practice)Head of corporate restructuringDeclarant for the trust in support of its motion to approve the states' stipulationControls the LLC as sole trustee of its sole member and votes and disposes of its sharesDirector of the blank check companyHealthcare analystHealthcare analystPresident and chair of the board; shares voting and dispositive power over the foundation's sharesSole trusteeBoard member (as listed by an aggregator)Co-founder and board memberDirectorBoard memberApplicant for payment of her indemnification expenses as an administrative expense of the estates (+6)Co-founder; director from 2006 and chief executive officer from 2010Healthcare analystBoard memberDirector and officerOfficerJoint bidder with New Mountain Capital at $2.53 a share; New Mountain withdrewHealthcare analystOfficerMember of the board of advisors (not the board of directors)Creator, funder with her affiliates, chief executive officer, president and one of three directorsMember of the board of directorsUnsecured creditor appointed to the official creditors' committeeHolder of Class A shares, reporting jointly with Richard Magides (5.02% in November 2024, 18.2% in March 2025; 14.55% and 7.95% of the vote on July 1, 2025)Uses the Singapore manager as its address for correspondence (c/o)23andMe GenomicsLLC23andMe Genomics LLCTTAM 2.0, LLCTTAM 2.0, LLC23andMe ResearchLLC23andMe Research LLC23andMe EmployeesLLC23andMe Employees LLCCazoo Group Ltd.Cazoo Group Ltd.Ardsley PartnersArdsley PartnersSir RichardBransonSir Richard BransonVG AcquisitionSponsor LLCVG Acquisition Sponsor LLCVirgin GroupHoldings LimitedVirgin Group Holdings LimitedBFT CLG (PTC)LimitedBFT CLG (PTC) LimitedBFT (PTC) LimitedBFT (PTC) LimitedVG AcquisitionCorp. III (VGACIII)VG Acquisition Corp. III (VGAC III)ServiceNow, Inc.ServiceNow, Inc.Snowflake, Inc.Snowflake, Inc.Deloitte LLPDeloitte LLPNodal ExchangeHoldings LLCNodal Exchange Holdings LLCTroper WojcickiFoundationTroper Wojcicki FoundationFoundation for theNationalInstitutes ofHealth, Inc.Foundation for the National Institutes of Health, Inc.Kenneth HillanKenneth HillanConvergeTechnologySolutions US LLCConverge Technology Solutions US LLCBreakthrough Prizein Life SciencesBreakthrough Prize in Life SciencesKaiser PermanenteBernard J. TysonSchool of MedicineKaiser Permanente Bernard J. Tyson School of MedicineAndor CapitalManagementAndor Capital ManagementCorvina HoldingsLimitedCorvina Holdings LimitedVirgin InvestmentsLimitedVirgin Investments LimitedJosh BaylissJosh BaylissVirgin Red LimitedVirgin Red LimitedVirginEntertainmentHoldings, Inc.Virgin Entertainment Holdings, Inc.Teresa BriggsTeresa BriggsJAND, Inc. (WarbyParker)JAND, Inc. (Warby Parker)Perlegen Sciences,Inc.Perlegen Sciences, Inc.Nodal Exchange LLCNodal Exchange LLCSusan WojcickiSusan WojcickiAnne WojcickiFoundationAnne Wojcicki FoundationRegeneronPharmaceuticals,Inc.Regeneron Pharmaceuticals, Inc.23andMe ResearchInstitute(formerly TTAMResearchInstitute)23andMe Research Institute (formerly TTAM Research Institute)ABeeC 2.0, LLCABeeC 2.0, LLCThe Anne WojcickiRevocable TrustU/A/D 9/2/09The Anne Wojcicki Revocable Trust U/A/D 9/2/09ZiplineInternational,Inc.Zipline International, Inc.Ryan BatenchukRyan BatenchukSC US (TTGP), Ltd.SC US (TTGP), Ltd.VG AcquisitionCorp. II (VGAC II)VG Acquisition Corp. II (VGAC II)EdisonInternationalEdison InternationalVirgin GalacticHoldings, Inc.Virgin Galactic Holdings, Inc.DocuSign, Inc.DocuSign, Inc.Pacific MutualHolding Co.Pacific Mutual Holding Co.Nodal Clear LLCNodal Clear LLCPaul CusenzaPaul CusenzaLPRXOne LLCLPRXOne LLCLemonaid CommunityPharmacy, Inc.Lemonaid Community Pharmacy, Inc.CorporationService CompanyCorporation Service CompanyLemonaid PharmacyHoldings Inc.Lemonaid Pharmacy Holdings Inc.Anne WojcickiAnne WojcickiChrome PharmacyHoldings, Inc.(formerly 23andMePharmacy Holdings,Inc.)A1Chrome Pharmacy Holdings, Inc. (formerly 23andMe Pharmacy Holdings, Inc.)A1: Chapter 11 filing (March 2025); liquidating plan effective December 5, 2025IncorporatingServices, LtdIncorporating Services, LtdBlok24, Inc.Blok24, Inc.New MountainCapital L.L.C.New Mountain Capital L.L.C.Passport Capital,LLCPassport Capital, LLCInvestor ABInvestor ABEvan LovellEvan LovellVirgin Green FundVirgin Green FundTPG CapitalTPG CapitalAJAX IAJAX ISidecar Health,Inc.Sidecar Health, Inc.LaboratoryCorporation ofAmerica HoldingsLaboratory Corporation of America HoldingsState ofCaliforniaState of CaliforniaJMB CapitalPartners Lending,LLCJMB Capital Partners Lending, LLCLemonaid Health,Inc.A1 · A10Lemonaid Health, Inc.A1: Chapter 11 filing (March 2025); liquidating plan effective December 5, 2025 · A10: Tracking-pixel class action against Lemonaid (2023; settled 2025)Chrome Holding Co.(formerly 23andMeHolding Co.)A1 · A4 · A5 · A6 · A7 · A8 · A9Chrome Holding Co. (formerly 23andMe Holding Co.)A1: Chapter 11 filing (March 2025); liquidating plan effective December 5, 2025 · A4: FTC demand, multistate and foreign regulators' inquiries into the 2023 breach (2024) · A5: U.S. data-breach class actions, centralised and settled (2023–2026) · A6: Canadian data-breach class actions (2023–2024; settled 2025) · A7: Proofs of claim of 42 state and D.C. governmental claimants settled for $18 million with conduct limits (2026) · A8: California Attorney General suit over the 2023 breach (2026; monetary claims barred by the plan injunction) · A9: States' adversary proceedings over the sale of genetic data (2025; injunction denied, sale approved)KR OP Tech, LLCKR OP Tech, LLCChromeCo, Inc.(formerly 23andMe,Inc.)A1 · A2 · A3 · A6 · A8 · A9ChromeCo, Inc. (formerly 23andMe, Inc.)A1: Chapter 11 filing (March 2025); liquidating plan effective December 5, 2025 · A2: UK Information Commissioner penalty of £2,310,000 (June 2025) · A3: Canadian and UK privacy commissioners found inadequate safeguards (2025) · A6: Canadian data-breach class actions (2023–2024; settled 2025) · A8: California Attorney General suit over the 2023 breach (2026; monetary claims barred by the plan injunction) · A9: States' adversary proceedings over the sale of genetic data (2025; injunction denied, sale approved)Jellyfish USLimitedJellyfish US LimitedGlobal BioDataTrustGlobal BioData TrustThe Vanguard GroupThe Vanguard GroupPeter J. TaylorPeter J. TaylorSouthernCalifornia EdisonCo.Southern California Edison Co.Space ExplorationTechnologies Corp.Space Exploration Technologies Corp.Maze Therapeutics,Inc.Maze Therapeutics, Inc.Richard SchellerRichard SchellerAarvikTherapeuticsAarvik TherapeuticsLPRXThree LLCLPRXThree LLCKrollRestructuringAdministration LLCKroll Restructuring Administration LLCWilliam G.RichardsWilliam G. RichardsGlaxo GroupLimitedGlaxo Group LimitedGSK plcGSK plcChrome Merger Sub,Inc.Chrome Merger Sub, Inc.Kathy L. HibbsKathy L. HibbsSophia Genetics SASophia Genetics SAElement PartnersElement PartnersGenomic HealthInc.Genomic Health Inc.Precisely, Inc.Precisely, Inc.ECMC FoundationECMC FoundationRoelof BothaRoelof BothaBlock, Inc.Block, Inc.Alector, Inc.Alector, Inc.DiCE MoleculesDiCE MoleculesHouston CasualtyCompanyHouston Casualty CompanyTelusInternationalServices LimitedTelus International Services LimitedLPRXTwo LLCLPRXTwo LLCChrome Holding Co.PlanAdministrationTrustChrome Holding Co. Plan Administration TrustState of TexasState of TexasFMR LLCFMR LLCAlvarez & MarsalNorth America, LLCAlvarez & Marsal North America, LLCAdventInternationalAdvent InternationalDouglas R. BrownDouglas R. BrownIonics,IncorporatedIonics, IncorporatedLinda AveyLinda AveyHumain VenturesHumain VenturesMongoDB, Inc.MongoDB, Inc.AquaVentureHoldingsAquaVenture HoldingsOricPharmaceuticals,Inc.Oric Pharmaceuticals, Inc.Genentech, Inc.Genentech, Inc.Boots UK LimitedBoots UK LimitedIan Alexander VanEveryIan Alexander Van EveryLemonaid HealthLimited (now BootsDigital HealthLimited)Lemonaid Health Limited (now Boots Digital Health Limited)Thomas B. WalperThomas B. WalperKPMG LLPKPMG LLPLandmark AmericanInsurance CompanyLandmark American Insurance CompanyExabeam, Inc.Exabeam, Inc.Deloitte & ToucheLLPDeloitte & Touche LLPSeven Seas WaterCorporationSeven Seas Water CorporationRedleaf GroupRedleaf GroupRock HealthRock HealthCloudera, Inc.Cloudera, Inc.Natera, Inc.Natera, Inc.Sequoia CapitalOperations, LLCSequoia Capital Operations, LLCCBS Radio Inc.CBS Radio Inc.BridgeBio Pharma,Inc.BridgeBio Pharma, Inc.Alliance BootsHoldings LimitedAlliance Boots Holdings LimitedHotwire, Inc.Hotwire, Inc.Joseph SelsavageJoseph SelsavageKyle PretschKyle PretschThe Nasdaq CapitalMarketThe Nasdaq Capital MarketLPharm CS LLCLPharm CS LLCForeScoutTechnologies, Inc.ForeScout Technologies, Inc.Mark JensenMark JensenArthur AndersenLLPArthur Andersen LLPControl4CorporationControl4 CorporationJim FrankolaJim FrankolaAriba, Inc.Ariba, Inc.Unity SoftwareInc.Unity Software Inc.IonQ, Inc.IonQ, Inc.Froedtert HealthSystem, Inc.Froedtert Health System, Inc.Unwired Planet,Inc.Unwired Planet, Inc.Red EclipseConsultingRed Eclipse ConsultingMunger, Tolles &Olson LLPMunger, Tolles & Olson LLPMetromileOperating Co.Metromile Operating Co.BambumetaVentures, LLCBambumeta Ventures, LLCLemonaid SPV, Inc.Lemonaid SPV, Inc.Richard HearnRichard HearnLatticeSemiconductorCorporationLattice Semiconductor CorporationJacuzzi BrandsJacuzzi BrandsMatthew KvardaMatthew KvardaValerie MontgomeryRiceValerie Montgomery RiceMorehouse Schoolof MedicineMorehouse School of MedicineUnitedHealth GroupInc.UnitedHealth Group Inc.First RepublicBankFirst Republic BankDomain AmericasLLCDomain Americas LLCAndre FernandezAndre FernandezCardlytics, Inc.Cardlytics, Inc.Getty ImagesHoldings, Inc.Getty Images Holdings, Inc.Day Break PartnersDay Break PartnersInnova CapitalPartnersInnova Capital PartnersPlainfield AssetManagement LLCPlainfield Asset Management LLCeGateway CapitaleGateway CapitalAuctus HoldingLtd.Auctus Holding Ltd.Neal MohanNeal MohanWolfspeed, Inc.Wolfspeed, Inc.Revlon, Inc.Revlon, Inc.Meharry MedicalCollegeMeharry Medical CollegeAnsys, Inc.Ansys, Inc.YouTube, Inc.YouTube, Inc.Sandra HernándezSandra HernándezCalifornia HealthCare FoundationCalifornia Health Care FoundationNCR CorporationNCR CorporationSachem AcquisitionCorp.Sachem Acquisition Corp.WL Ross & Co. LLCWL Ross & Co. LLCLPharm RX LLCLPharm RX LLCJames B. LockhartIIIJames B. Lockhart IIIAllied WorldSpecialtyInsurance CompanyAllied World Specialty Insurance CompanyWorkday, Inc.Workday, Inc.Broadview CapitalBroadview CapitalStarbucks Corp.Starbucks Corp.Patrick ChungPatrick ChungPhilo, Inc.Philo, Inc.TEAM, Inc.TEAM, Inc.Skillsoft Corp.Skillsoft Corp.Artradis FundManagement Pte LtdArtradis Fund Management Pte LtdBlackbaud, Inc.Blackbaud, Inc.Covered CaliforniaCovered CaliforniaBlackstoneInfrastructureStrategies L.P.Blackstone Infrastructure Strategies L.P.FaZe Holdings,Inc.FaZe Holdings, Inc.NewView CapitalFund I, L.P.NewView Capital Fund I, L.P.G Squared EquityManagement LPG Squared Equity Management LPVirgin MoneyHoldings (UK)Virgin Money Holdings (UK)LPharm INS LLCLPharm INS LLCDylan RunneDylan RunneFarallon Partners,L.L.C.Farallon Partners, L.L.C.Stitch Fix, Inc.Stitch Fix, Inc.WRLD3D Ltd.WRLD3D Ltd.XfundXfundXfund 3, L.P.Xfund 3, L.P.Yodlee, Inc.Yodlee, Inc.Richard MagidesRichard MagidesZentreeInvestmentsLimitedZentree Investments LimitedZentree InvestmentManagement Pte LtdZentree Investment Management Pte LtdWeWork, Inc.WeWork, Inc.LMND MedicalGroup, Inc.LMND Medical Group, Inc.

Solid line: documented. Amber dashed: reported. Grey dotted: hypothesis. One arrow: the relationship as stated; two arrows: reciprocal; no arrow: symmetric. A path between two parties does not transfer an allegation from one to the other.

every party and relationship in full, as text ↓

Information markers
  • A1 · Chapter 11 filing (March 2025); liquidating plan effective December 5, 2025 — Lemonaid Health, Inc.
  • A4 · FTC demand, multistate and foreign regulators' inquiries into the 2023 breach (2024) — Chrome Holding Co. (formerly 23andMe Holding Co.)
  • A5 · U.S. data-breach class actions, centralised and settled (2023–2026) — Chrome Holding Co. (formerly 23andMe Holding Co.)
  • A6 · Canadian data-breach class actions (2023–2024; settled 2025) — ChromeCo, Inc. (formerly 23andMe, Inc.)
  • A7 · Proofs of claim of 42 state and D.C. governmental claimants settled for $18 million with conduct limits (2026) — Chrome Holding Co. (formerly 23andMe Holding Co.)
  • A8 · California Attorney General suit over the 2023 breach (2026; monetary claims barred by the plan injunction) — ChromeCo, Inc. (formerly 23andMe, Inc.)
  • A9 · States' adversary proceedings over the sale of genetic data (2025; injunction denied, sale approved) — ChromeCo, Inc. (formerly 23andMe, Inc.)
  • A2 · UK Information Commissioner penalty of £2,310,000 (June 2025) — ChromeCo, Inc. (formerly 23andMe, Inc.)
  • A3 · Canadian and UK privacy commissioners found inadequate safeguards (2025) — ChromeCo, Inc. (formerly 23andMe, Inc.)
  • A10 · Tracking-pixel class action against Lemonaid (2023; settled 2025) — Lemonaid Health, Inc.

Markers apply only to the named participant. They do not transfer allegations to connected parties.

Participants 208

Subject

Leadership

Group companies

Counterparties

Historical

Other

Relationship register 267

chronology

  1. Anne Wojcicki, Linda Avey and Paul Cusenza found 23andMe, Inc. c-gov-founding
  2. VG Acquisition Corp. is incorporated in the Cayman Islands as a blank check company c-spac-blank-check
  3. VGAC completes its initial public offering c-spac-blank-check
  4. VGAC and 23andMe announce their merger agreement c-spac-announcement
  5. VGAC shareholders approve the business combination and ten-vote Class B stock c-spac-vote c-spac-board-elect
  6. VGAC becomes 23andMe Holding Co. and acquires 23andMe, Inc. c-spac-closing c-ctl-2021
  7. 23andMe acquires Lemonaid Health for $400 million c-lem-acquisition
  8. The credential-stuffing attack begins, according to the Canadian and UK regulators c-br-regulator-scope
  9. Tracking-pixel class action filed against Lemonaid Health c-lem-pixel-suit
  10. The UK subsidiary Lemonaid Health Limited passes to Boots UK c-lem-uk-disposal
  11. The company discloses the data breach c-br-company-account c-st-litigation-scale
  12. The board forms a Special Committee to review Wojcicki's proposals c-gov-special-committee
  13. Federal breach class actions centralised as MDL No. 3098 c-st-mdl
  14. Wojcicki holds 49.75% of the vote, according to the 2024 proxy c-ctl-2024-wojcicki
  15. Wojcicki proposes to take the company private at $0.40 a share c-gov-go-private-2024
  16. All seven independent directors resign c-gov-resignations
  17. Three new independent directors join the board c-gov-new-board
  18. Therapeutics programmes end and about 40% of staff are cut c-ch-cutbacks
  19. The Special Committee announces a review of strategic alternatives c-gov-strategic-review
  20. Wojcicki and New Mountain Capital propose $2.53 a share c-gov-feb-march-2025
  21. Chapter 11 filing; Wojcicki steps down as chief executive c-ch-filing c-gov-ceo-resignation
  22. Court authorises the JMB debtor-in-possession loan c-ch-dip
  23. Nasdaq delisting takes effect c-id-delisting
  24. FTC Chairman's letter on the sale of customer data c-sale-ftc-letter
  25. Regeneron named successful bidder, TTAM backup c-sale-regeneron
  26. UK Information Commissioner fines 23andMe, Inc. £2,310,000 c-br-ico-penalty
  27. Twenty-eight states and D.C., and Texas, sue over the sale of genetic data c-sale-states-suits
  28. ABeeC 2.0 converts its Class B shares into Class A c-ctl-conversion
  29. TTAM chosen as winning bidder at $305 million c-sale-ttam-wins
  30. Court approves the sale to TTAM c-sale-opinion c-sale-closing
  31. Sale to TTAM closes for $302.5 million; DIP loan repaid c-sale-closing c-ch-dip
  32. 23andMe Holding Co. renamed Chrome Holding Co. c-id-rename
  33. Debtors file their joint plan c-ch-plan-august
  34. Agreement to sell Lemonaid to Lemonaid SPV, Inc. for $10 million c-lem-spv-agreement
  35. Court approves the arbitration settlement covering about 32,000 claims c-st-arbitration
  36. Court confirms the liquidating plan c-ch-confirmation
  37. Form 15-12G terminating the registration of the securities c-id-15-12g
  38. Plan effective: shares cancelled, Plan Administration Trust formed c-ch-confirmation c-ch-plan-trust
  39. Lemonaid sale reported closed c-lem-closing
  40. Wojcicki applies for payment of her indemnification expenses c-ch-wojcicki-application
  41. All cases closed except Chrome Holding Co.'s c-ch-case-closing
  42. Final approval of the U.S. breach class settlement c-st-us-final
  43. California's Attorney General sues over the breach c-st-ca-suit c-br-ca-allegations
  44. Bankruptcy court bars the monetary claims of California's suit c-st-ca-enforcement-order
  45. Stipulation with 41 states and D.C.: $18 million and conduct limits c-st-states-claims
  46. District court dismisses the appeal against the sale order c-sale-district-court

cite this dossier

DossierTwist, “23andMe Holding Co.: control, breach, bankruptcy and the sale of genetic data”, dt.024, 25 October 2026, https://dossiertwist.com/dossiers/case-23andme-holding-co/

Free to read, cite and republish with credit under CC BY 4.0: credit “DossierTwist” and link to the dossier.

Data: JSON, CSV and the network graph.

share

We listen to all sides: responses are shown next to the claims they answer. To send a correction or a reply, write to dossiertwist@proton.me.